Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 first-in-human study of CRN09682 in SST2-expressing neuroendocrine neoplasms and other solid tumors
2025-521672-60-00Phase 2Authorised
- Sponsor
- Crinetics Pharmaceuticals
- Start
- Dec 2025
- Modality
- Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 6
01
Overview
Phase 2, open-label trial of CRN09682 in apudoma (NET) and Nonhematologic neoplasms (2 arms), sponsored by Crinetics Pharmaceuticals. Primary endpoints: Incidence and severity of dose-limiting toxicities, Incidence and severity of adverse events and serious adverse events and 3 more. Planned start Dec 2025; status: authorised.
02
Drugs
CRN09682
03
Conditions
apudoma (NET)Nonhematologic neoplasms
Beyond the preview
Go deeper on 2025-521672-60-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521672-60-00.